ECCO 2026

IL-23 - is this the good-bye from systemic therapy?

Early treatment concepts with infliximab

Advances in anti‑fibrotic therapy

Update on upadacitinib vs. risankizumab after anti-TNF…

IL-23: from real-world to special patient population

Deeper endpoints in clincial trials and RW

Fistulizing disease - what can we do better?

Exciting new data on surgery - for all patient groups?

Evolving landscape of anti-fibrotic therapy in IBD

Diet as prevention and early intervention in Crohn’s…

Molecular signature–driven therapy

Molecular medicine driving treatment decisioning!?

Should we stop thiopurines in IBD patients who are…

Switching to subcutaneous infliximab is safe as a…

What is the best treatment approach in IBD?

Molekulare Medizin als Wegweiser für…

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

Top-down- versus Step-up-Therapie beim Morbus Crohn

Do we need immediate postoperative prophylaxis?

LIR!C 10 yrs FUP: Is there a benefit for surgery?

Top-down vs. step-up therapy in CD

JAK–STAT inhibition as a therapeutic approach for…

Should we prevent or treat post-operative recurrence in…

Early use of infliximab positively influences longterm…

Früher Einsatz von Infliximab verbessert das…

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

JAK-STAT Hemmung zur Fistel-Therapie

Faut-il prévenir ou traiter la récidive postopératoire…

Top-down vs. Step-up Therapie beim Morbus Crohn

Long term outcomes after appendicectomy in UC (5 year…

Steroid sparing effect of filgotinib in UC

Pouch surgery: only for expert centers

Combination therapy with tofacitinib and…

ASUC: smarter use of third-line rescue therapy

Tofacitinib-Steroid-Kombination bei ASUC

Resultados a largo plazo tras apendicectomía en colitis…

ASUC: Derde‑lijn­therapie slimmer inzetten

Effetto steroid-sparing di filgotinib nella colite…

Strategia treat-to-target nella colite ulcerosa

Obefazimod as antifibrotic agent

The risk of colorectal neoplasia in IBD

Risque de cancer colorectal dans les MICI

Langetermijn data van IL‑23 inhibitoren

Outside the gut - efficacy uf guselkumab in…

UPA vs RISA in Crohn’s disease – a decision dilemma

Ustekinumab is effective and safe for paediatric…

Histo-endoscopic outcomes of upadacitinib in CD

Guselkumab may improve and prevent extraintestinal…

Guselkumab può migliorare e prevenire le manifestazioni…

UPA vs RISA w chorobie Leśniowskiego-Crohna – sztuka…

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Mirikizumab is able to induce disease clearence in…

Histo-endoscopic outcomes of guselkumab in UC

Short-term effectiveness and safety of Mirikizumab in…

Early and durable response with guselkumab

Does colectomy reduce the risk of death in UC?

Short term transmural healing detected by US in CD…

Etrasimod in the milder moderate UC patients

Etrasimod efficacy in mildly-to-moderately active UC…

Efficacy and safety of vedolizumab + upadacitinib as…

Long-term efficacy and safety of risankizumab in UC

Vedolizumab combined with upadacitinib vs Vedolizumab…

Est-ce que la colectomie réduit le risque de décès dans…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Efectividad y seguridad a corto plazo de Mirikizumab en…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Efficacia e sicurezza a lungo termine di risankizumab…

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Valutazione a breve termine della guarigione…

AGMB-129, Ontunisertib, new MoA in patients with…

Impact of icotrokinra on biomarkers in UC

Icotrokinra and systemic inflammatory burden in UC

Ontunisertib - ALK5 blockage in fistulizing CD

The STENOVA Trial. Ontunisertib shows promising results…

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

B-cells step into the spotlight

תאי B במרכז העניינים

Impact de l’icotrokinra sur les biomarqueurs dans la…

Apendektomie - eine neue Therapieoption bei Colitis…

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

L’accumulo di cellule citotossiche CD4+ caratterizza la…

AGMB-129, Ontunisertib, nueva terapia para pacientes…

Ikotrokinkra a stan zapalny w colitis ulcerosa

AI endoscopic reads in acute severe UC change the…

ADHD and autism in IBD – the same or different story?

IBDMED מעבר לאזור הים התיכון